Interaction between human immunodeficiency virus (HIV) drugs (non-nucleoside reverse transcriptase inhibitors [NNRTIs]) and anti-platelet agents

Not Applicable

Completed

• Conditions: Human immunodeficiency virus (HIV); Infections and Infestations; Human immunodeficiency virus

• Registration Number: ISRCTN68035289
• Lead Sponsor: Royal Liverpool University Hospital and the University of Liverpool?s Biomedical Research Centre (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2009-12-15
• Study Start: 2009-12-17
• Last Update Posted: 30 May 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

1. Aged greater than 18 years, either sex
2. On efavirenz (EFV) or nevirapine (NVP) containing regimen for greater than or equal to 6 months
3. Viral load less than or equal to 40 copies/ml and any CD4 count
4. No laboratory evidence of NNRTI toxicity:
4.1. Alanine aminotransferase (ALT) less than or equal to upper limit of normal (ULN)
4.2. Bilirubin less than or equal to ULN
4.3. Albumin greater than or equal to 30 g
4.4. Creatinine less than or equal to ULN
5. Not pregnant (for contraception, patients would be advised to use non-oestrogen based contraceptive devices)
6. No inter-current acute illness
7. No past medical history of coronary heart disease
8. No history of bleeding diathesis
9. No history of allergy to thienopyridines

Exclusion Criteria

1. Unable to provide informed consent
2. Known or suspected poor adherence to anti-retroviral therapy (ART)
3. Continuing intravenous (IV) drug user
4. On a HIV protease inhibitor or any known P450 inhibitors or inducers
5. Platelets less than or equal to 100 x 10^9/l
6. Neutrophils less than or equal to 1.0 x 10^9/ml

Study & Design

• Study Type: Interventional
• Study Design: Not specified